31 August 2017
Shield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017
London, UK, 31 August 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announced that Carl Sterritt, Chief Executive Officer, will present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017 at 9:05 AM ET in New York. Mr. Sterritt will give a corporate overview, review the Company’s late-stage and commercial product portfolio, and provide an update on upcoming milestones, including key clinical trial readouts and potential subsequent regulatory submission.
About Shield Therapeutics
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals, which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.
For further information please contact:
Shield Therapeutics plc +44 (0) 207 186 8500
Joanne Estell, Chief Financial Officer
Karl Keegan, Corporate Development Director
Nominated Adviser and Joint Broker +44 (0)20 3100 2222
Liberum Capital Limited
Joint Broker +44 (0)20 7418 8900
Peel Hunt LLP
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
U.S Investor Relations + 1 (212)-599-1265
Lazar Partners Ltd.